Holen Sie sich die Stockscreener-App
9.66
1.15%
0.11
Vorhandelsmarkt:
9.63
-0.03
-0.31%
Schlusskurs vom Vortag:
$9.55
Offen:
$9.55
24-Stunden-Volumen:
230.18K
Relative Volume:
0.48
Marktkapitalisierung:
$178.98M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-84.53M
KGV:
-1.6614
EPS:
-5.8145
Netto-Cashflow:
$-73.65M
1W Leistung:
+4.43%
1M Leistung:
+25.45%
6M Leistung:
+16.25%
1J Leistung:
+15.41%
1-Tages-Spanne:
$9.46
$9.88
1-Wochen-Bereich:
$8.95
$9.88
52-Wochen-Spanne:
$7.12
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.66 | 178.98M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
496.50 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.95 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.49 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.79 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.13 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as chief medical officer - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz
Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer - marketscreener.com
Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals names Leonardo Nicacio as CMO - Investing.com
Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan
Corbus adds new medical chief ahead of CRB-701 cancer study - Stock Titan
Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Risk Channels and Responsive Allocation - Stock Traders Daily
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2000 Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark - marketscreener.com
CRBP Q1 2026 Earnings: EPS Beats Estimates Amid Pipeline ProgressAnalyst Consensus Shift - dars.gov.et
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000E Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2500 Index - marketscreener.com
CRBP Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Price to sales forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – BOATS:CRBP - TradingView
Corbus Pharmaceuticals (CRBP) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
CRBP Maintained by Mizuho -- Price Target Lowered to $34 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $34 - Moomoo
Corbus Pharmaceuticals Holdings Inc (CRBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
(CRBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRBP News | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Corbus Pharmaceuticals Sharesanalyst consensus snapshot - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $52 - Moomoo
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 By Investing.com - Investing.com Nigeria
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Stock (US21833E1038): Nasdaq price action in focus on a quiet news day - Ad-hoc-news.de
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):